Moderna Inc. saw its stock climb sharply after the company issued a statement confirming it is engaged in early-stage vaccine research focused on hantaviruses. The move came into public view on Friday and was followed by a 16% rise in the company’s shares.
According to the company statement, Moderna has been working on preliminary vaccine development in partnership with the U.S. Army Medical Research Institute of Infectious Diseases. Moderna also named the Vaccine Innovation Center at Korea University College of Medicine as a collaborator in efforts to explore a potential immunization.
The statement made clear that the work is at an early stage and remains ongoing - language the company used to frame these activities as part of a broader responsibility to pursue countermeasures against emerging infectious diseases. Moderna said its announcement confirmed prior reports about its research on this pathogen.
The disclosure of Moderna’s research activity arrived after an outbreak linked to the Dutch-flagged cruise ship Hondius. The World Health Organization identified at least six confirmed cases and two suspected cases tied to the incident. The outbreak has been fatal for three passengers.
At the same time, public health experts have downplayed the likelihood that the hantavirus event aboard the ship will evolve into a larger public-health threat. Moderna’s statement and the public-health assessments together highlight a balance between early-stage scientific work and assessments of current community risk.
Investors reacted quickly to the confirmation of Moderna’s hantavirus research, pricing that development into the share price on the same day the company issued its statement. The company’s declaration emphasized the preliminary nature of the work while acknowledging partnerships with established research institutions.
Context and implications
- Moderna confirmed active, early-stage hantavirus vaccine research in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Korea University’s Vaccine Innovation Center.
- The company’s shares rose 16% following the confirmation.
- The disclosure followed an outbreak aboard the cruise ship Hondius in which the World Health Organization reported multiple confirmed and suspected cases and three deaths; public health experts have largely downplayed broader risk.